Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 1

Conditions

Advanced Solid Tumor 130Advanced Solid Tumors 122Solid Tumor 101Mesothelioma, Malignant 48Solid Tumors 43Mesothelioma 42Hematopoietic and Lymphatic System Neoplasm 30Solid Tumor, Adult 27Retinoblastoma 20Pancreatic Neoplasms 14Carcinoma, Non-Small-Cell Lung 14Ovarian Neoplasms 13Lung Neoplasms 13Neoplasms 11Advanced Malignant Solid Tumor 11Advanced or Metastatic Solid Tumors 10Solid Tumors, Adult 9Sarcoma 9Hematopoietic and Lymphoid System Neoplasm 9Advanced Malignant Solid Tumors 9Stomach Neoplasms 8Solid Tumor Malignancies 8Neoplasm Metastasis 8Melanoma 8Malignant Solid Tumors 8Malignant Solid Neoplasm 8Locally Advanced or Metastatic Solid Tumors 8Kidney Neoplasms 8Colorectal Neoplasms 8Advanced/Metastatic Solid Tumors 8

Interventions

repaglinide 1Tablets 1Rosuvastatin Calcium 1Metformin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × TP53 Y220C Mutation × Other solid neoplasm × Clear all
NCT07372625 2026-03-12

A Study to Investigate the Effects of Multiple Doses of Rezatapopt on the Pharmacokinetics of Metformin, Rosuvastatin, Repaglinide, and Midazolam in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation.

PMV Pharmaceuticals, Inc

Phase 1 Recruiting
14 enrolled
Other solid neoplasm

TP53 Y220C Mutation

Data powered by HemOnc (CC BY 4.0) Colophon âš¡